• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by NeOnc Technologies Holdings Inc.

    4/25/25 3:56:55 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NTHI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    NEONC TECHNOLOGIES HOLDINGS, INC.

    (Name of Issuer)


    COMMON STOCK, par value $0.0001 per share

    (Title of Class of Securities)


    64051A101

    (CUSIP Number)


    Dr. Thomas Chen
    23975 Park Sorrento, Suite 205
    Calabasas, CA, 91302
    310 663 7831

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    03/26/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    64051A101


    1 Name of reporting person

    Amir F. Heshmatpour
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    6,213,499.00
    8Shared Voting Power

    275,000.00
    9Sole Dispositive Power

    6,213,499.00
    10Shared Dispositive Power

    275,000.00
    11Aggregate amount beneficially owned by each reporting person

    6,488,499.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox checked
    13Percent of class represented by amount in Row (11)

    34.3 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    (1) Aggregate amount owned includes 275,000 shares held by Reporting Person's minor daughter, 3,714,020 shares of common stock held by AFH Holding & Advisory, LLC of which Reporting Person is the sole member, and 1,024,479 shares of common stock held by HCWG LLC of which Reporting Person holds 25% of the membership interests and is the managing member.


    SCHEDULE 13D

    CUSIP No.
    64051A101


    1 Name of reporting person

    AFH Holding & Advisory, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    3,714,020.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    3,714,020.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    3,714,020.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    19.64 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    64051A101


    1 Name of reporting person

    HCWG LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    1,024,479.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    1,024,479.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    1,024,479.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.42 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    COMMON STOCK, par value $0.0001 per share
    (b)Name of Issuer:

    NEONC TECHNOLOGIES HOLDINGS, INC.
    (c)Address of Issuer's Principal Executive Offices:

    23975 Park Sorrento, Suite 205, Calabasas, CALIFORNIA , 91302.
    Item 1 Comment:
    This Schedule 13D relates to the common stock, par value $0.0001 per share (the "Common Stock"), of NeOnc Technologies Holdings, Inc. ("Issuer" or "NeOnc"). Following the direct listing of Issuer's Common Stock on the Nasdaq Global Market, issued and outstanding Common Stock totaled 18,908,025 shares.
    Item 2.Identity and Background
    (a)
    This Schedule 13D is filed on behalf of Amir. F. Heshmatpour, AFH Holding & Advisory, LLC ("AFH Holding") and HCWG LLC ("HCWG"), who are collectively referred to herein as "Reporting Persons".
    (b)
    The address of each Reporting Person is 23975 Park Sorrento, Suite 205, Calabasas, CA 91302.
    (c)
    Amir F. Heshmatpour is the sole member of AFH Holding and the managing member of HCWG. AFH Holding is a family office and holding company. HCWG is a Delaware limited liability company.
    (d)
    During the last five years, no Reporting Person has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    Within the last five years, no Reporting Person has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction nor been subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    Amir F. Heshmatpour is a citizen of the United States. Each of AFH Holding and HCWG is a Delaware limited liability company.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Exercise of warrant held by HCWG. See also Item 4 below.
    Item 4.Purpose of Transaction
     
    In connection with Issuer's direct listing on the Nasdaq Global Market on March 26, 2025, HCWG transacted a cashless exercise of a warrant issued by the Company for 312,500 shares of common stock. The exercise price of the warrant was $12 per share and the cashless withholding of shares was executed at $25 per share resulting in withholding of 162,500 shares and acquisition of 150,000 shares of common stock in the transaction.
    Item 5.Interest in Securities of the Issuer
    (a)
    See Item 11 of the cover page for each Reporting Person.
    (b)
    See Items 7 and 9 of the cover page for each Reporting Person.
    (c)
    See Item 4 above.
    (d)
    See Item 4 above.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    None.
    Item 7.Material to be Filed as Exhibits.
     
    Not applicable.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Amir F. Heshmatpour
     
    Signature:/s/ Amir F. Heshmatpour
    Name/Title:Amir F. Heshmatpour
    Date:04/25/2025
     
    AFH Holding & Advisory, LLC
     
    Signature:/s/ Amir F. Heshmatpour, Member
    Name/Title:Amir F. Heshmatpour, Member
    Date:04/25/2025
     
    HCWG LLC
     
    Signature:/s/ Amir F. Heshmatpour, Managing Member
    Name/Title:Amir F. Heshmatpour, Managing Member
    Date:04/25/2025
    Get the next $NTHI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTHI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NTHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

    CALABASAS, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") for the purchase and sale of up to 2,222,222 shares of common stock and five-year warrants to purchase up to 2,222,222 shares of common stock at a per share exercise price of $9.00 at a combined purchase price of $7.20, that is expected to result in gross proceeds of up to approximately $16 million to the Company. NeO

    1/30/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Reports Updated Clinical Results

    CALABASAS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced updated clinical results from its ongoing Phase 1/2a and compassionate-use experience evaluating intranasal NEO100 in patients with recurrent WHO Grade III/IV IDH1-mutant astrocytoma. Since the Company's prior announcement and 8K event on November 12, 2025, an additional patient has achieved both durable long-term survival and radiographic remission, further strengthening the clinical signal observed with intranasal NEO100

    12/15/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

    CALABASAS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company developing brain-penetrant therapeutics for central nervous system (CNS) cancers, today announced newly published preclinical findings from a research collaboration at the University of Southern California (USC). The study, now available on bioRxiv (https://www.biorxiv.org/content/10.1101/2025.11.25.690556v1), demonstrates that ultrasound further enhances and amplifies NEO100's therapeutic potency, driving strong antitumor effects across multiple primary and metastatic brain tumor types. Utilizing an AI-driven, 3D-bioprinted New Approach Methodol

    12/1/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Heshmatpour Amir F bought $119,600 worth of CommonStock (20,000 units at $5.98) and bought $65,060 worth of shares (10,000 units at $6.51), increasing direct ownership by 1% to 2,992,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    11/24/25 9:10:01 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Clinical Officer Neman-Ebrahim Yousha bought $7,359 worth of shares (1,100 units at $6.69), increasing direct ownership by 0.83% to 134,260 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    11/24/25 5:46:38 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Heshmatpour Amir F bought $14,785 worth of CommonStock (2,000 units at $7.39), increasing direct ownership by 0.11% to 1,762,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    5/23/25 9:31:11 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    SEC Filings

    View All

    SEC Form S-1 filed by NeOnc Technologies Holdings Inc.

    S-1 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    2/6/26 4:48:06 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

    8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    1/29/26 3:04:39 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by NeOnc Technologies Holdings Inc.

    EFFECT - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    12/29/25 12:15:39 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Heshmatpour Amir F bought $119,600 worth of CommonStock (20,000 units at $5.98) and bought $65,060 worth of shares (10,000 units at $6.51), increasing direct ownership by 1% to 2,992,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    11/24/25 9:10:01 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Chiang Ming-Fu (Alan) claimed ownership of 2,190,049 shares (SEC Form 3)

    3 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    11/24/25 6:13:12 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Clinical Officer Neman-Ebrahim Yousha bought $7,359 worth of shares (1,100 units at $6.69), increasing direct ownership by 0.83% to 134,260 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    11/24/25 5:46:38 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Financials

    Live finance-specific insights

    View All

    NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update

    CALABASAS, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended September 30, 2025, and provided an update on recent operational achievements and upcoming milestones. Third Quarter & Recent Corporate Highlights Middle East – NuroMENA, the UAE-based subsidiary, advanced its regional partnerships by appointing His Highness Sheikh Nahyan bin Zayed Al Nahyan as Executive Chairman, signing a Master Services Agreement with M42's IROS, and completing ADGM incorpora

    11/14/25 4:01:00 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

    CALABASAS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the completion of full patient enrollment in its ongoing NEO100-1 Phase 2a clinical trial. The trial is evaluating the company's lead therapeutic candidate, NEO100, for the treatment of recurrent isocitrate dehydrogenase 1 (IDH1)–mutant high-grade glioma (WHO Grade III and IV). The Company anticipates reporting preliminary data from this fully enrolled cohort in approximately six months, during the second quarter of 2026. "Compl

    11/13/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

    CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant brain tumors and central nervous system (CNS) disorders, today announced that it will host an investor conference call and webcast on Wednesday, November 12, 2025, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time (prior to market open). During the call, members of the NTHI management team and independent members of the company's Scientific Advisory Board (SAB) will present data updates from the Company's ongoing Phase 1/2a NEO100-1 clinical trial and

    11/7/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Leadership Updates

    Live Leadership Updates

    View All

    NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth

    CALABASAS, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that its Board of Directors has appointed Amir Heshmatpour as Chief Executive Officer. Mr. Heshmatpour, who was appointed President in April, will assume the CEO role effective immediately, continuing to serve as Executive Chairman of the Board. Dr. Thomas Chen, the company's founder, will transition from the CEO role to focus exclusively on his positions as Chief Medical Officer, Chief Scientific Officer, and member of the Board of Di

    11/4/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board

    CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. David M. Ashley to its scientific advisory board. Dr. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and the Director of The Preston Robert Tisch Brain Tumor Center at Duke University. Amir F. Heshmatpour, Executive Chairman & President, of NeOnc Technologies, commented, "We are privileged to have Dr. David M. Ashley MBBS (Hons), FRACP, PhD, of Duke University on NeOnc's Scientific Adv

    10/2/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, to Its Scientific Advisory Board

    CALABASAS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the appointment of Dr. Alexandra M. Miller to its scientific advisory board. Dr. Miller is the Chief of the Neuro-oncology Program and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, where she specializes in treating patients with primary brain tumors. "We are thrilled to welcome Dr. Alexandra Miller to our Scientific Advisory Board," said Amir F. Heshmatpour, Executive Chairman and P

    10/1/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care